Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.pone.0253977 http://scihub22266oqcxt.onion/10.1371/journal.pone.0253977 34214116!8253392!34214116     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PLoS+One 2021 ; 16 (7): e0253977 Nephropedia Template TP {{tp|p=34214116|t=2021. Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection |pdf=|usr=}}{{34214116}} gab.com Text Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection JO: PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=34214116 #FOAvip SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of the antibody response in relation to the outcome we performed a study in hospitalized COVID-19 patients. As comparison we also investigated the time course of the antibody response in SARS-CoV-2 asymptomatic subjects. Study results show that patients produce a strong antibody response to SARS-CoV-2 with high correlation between different viral antigens (spike protein and nucleoprotein) and among antibody classes (IgA, IgG, and IgM and neutralizing antibodies). The antibody peak is reached by 3 weeks from hospital admission followed by a sharp decrease. No difference was observed in any parameter of the antibody classes, including neutralizing antibodies, between subjects who recovered or with fatal outcome. Only few asymptomatic subjects developed antibodies at detectable levels. Twit Text FOAVip Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection ????PLoS One http://www.kidney.de/pget.php?&tw=1&pmid=34214116 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34214116 #FOAvip English Wikipedia <ref>{{Cite pmid|34214116}}</ref> Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection #MMPMID34214116 Marchi S; Viviani S; Remarque EJ; Ruello A; Bombardieri E; Bollati V; Milani GP; Manenti A; Lapini G; Rebuffat A; Montomoli E; Trombetta CM PLoS One 2021[]; 16 (7): e0253977 PMID34214116show ga SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of the antibody response in relation to the outcome we performed a study in hospitalized COVID-19 patients. As comparison we also investigated the time course of the antibody response in SARS-CoV-2 asymptomatic subjects. Study results show that patients produce a strong antibody response to SARS-CoV-2 with high correlation between different viral antigens (spike protein and nucleoprotein) and among antibody classes (IgA, IgG, and IgM and neutralizing antibodies). The antibody peak is reached by 3 weeks from hospital admission followed by a sharp decrease. No difference was observed in any parameter of the antibody classes, including neutralizing antibodies, between subjects who recovered or with fatal outcome. Only few asymptomatic subjects developed antibodies at detectable levels. |*Asymptomatic Infections[MESH] |Aged[MESH] |Antibodies, Neutralizing/*biosynthesis/blood/immunology[MESH] |Antibodies, Viral/*biosynthesis/blood/immunology[MESH] |COVID-19/*immunology/mortality[MESH] |Comorbidity[MESH] |Female[MESH] |Hospitalization[MESH] |Humans[MESH] |Immunoglobulin A/biosynthesis/blood/immunology[MESH] |Immunoglobulin G/biosynthesis/blood/immunology[MESH] |Immunoglobulin M/biosynthesis/blood/immunology[MESH] |Length of Stay[MESH] |Male[MESH] |Middle Aged[MESH] |Patient Admission[MESH] |Retrospective Studies[MESH]Characterization of antibody response in asymptomatic and symptomatic (epmc).pdf DeepDyve Pubget Overpricing